Dr. Amitkumar Mehta, MD
Hematology & Oncology (Hematology & Oncology Physician)
13400 E Shea Blvd
Scottsdale, AZ 85259
Who else practices at this address →
Maricopa County includes primary care (13% of residents) and dental (0% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 24
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 217
Licensed in Alabama since 2012, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
AZ license 78651 · AL license MD31391 (first issued 2012; active) · AL license 31391 (first issued 2012; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Alabama Hospital Birmingham, AL
- Mayo Clinic Hospital Phoenix, AZ
Medical groups
- University of Alabama Health Services Foundation, PC (2,814 clinicians)
- Mayo Clinic Arizona (1,626 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 217
- Services billed
- 786
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 290 | 163 |
| Established patient office or other outpatient visit, 40-54 minutes | 136 | 84 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 79 | 20 |
| New patient office or other outpatient visit, 60-74 minutes | 31 | 31 |
| Hospital discharge day management, 30 minutes or less | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Scottsdale, AZ | 208 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Scottsdale, AZ | 160 |
| Calquence (acalabrutinib maleate) | 107 |
| Prednisone Other prescribers in Scottsdale, AZ | 82 |
| Imbruvica (ibrutinib) | 71 |
| Venclexta (venetoclax) | 61 |
| Oxycodone Hcl Other prescribers in Scottsdale, AZ | 41 |
| Gabapentin Other prescribers in Scottsdale, AZ | 40 |
| Brukinsa (zanubrutinib) | 39 |
| Dexamethasone Other prescribers in Scottsdale, AZ | 37 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 69 payments worth $150,368 in total to this clinician.
| Incyte Corporation | $41,520 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $38,010 |
| Adc Therapeutics America, Inc. | $21,781 |
| AstraZeneca Pharmaceuticals LP | $19,383 |
| Kite Pharma, Inc. | $16,459 |
| Genentech USA, Inc. | $5,813 |
| Pfizer Inc. | $2,520 |
| Novartis Pharmaceuticals Corporation | $2,100 |
| Compensation for services other than consulting (speaking, faculty) | $75,923 |
|---|---|
| Consulting Fee | $41,622 |
| Honoraria | $19,200 |
| Travel and Lodging | $12,615 |
| Food and Beverage | $1,008 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Kite Pharma, Inc. May 4, 2025 | Consulting Fee Yescarta · CELLT Company’s description;4099864;GTF;10411740 | $15,210 |
| Adc Therapeutics America, Inc. Sep 30, 2025 | Honoraria ZYNLONTA · ONCOLOGY | $11,900 |
| E.r. Squibb & Sons, L.l.c. Mar 14, 2025 | Compensation for services other than consulting (speaking, faculty) BREYANZI · Oncology | $8,280 |
| AstraZeneca Pharmaceuticals LP May 8, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $5,740 |
| Incyte Corporation Apr 23, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $5,480 |
| Incyte Corporation Aug 27, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $5,480 |
| Adc Therapeutics America, Inc. Apr 8, 2025 | Honoraria ZYNLONTA · ONCOLOGY | $5,475 |
| AstraZeneca Pharmaceuticals LP Jun 13, 2025 | Consulting Fee CALQUENCE · Oncology | $4,920 |
| E.r. Squibb & Sons, L.l.c. May 30, 2025 | Compensation for services other than consulting (speaking, faculty) BREYANZI · Oncology | $4,140 |
| Incyte Corporation Jun 24, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $4,110 |
All 54 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Dec 16, 2025 | Consulting Fee | $4,100 |
| Genentech USA, Inc. Dec 4, 2025 | Consulting Fee Polivy · BioOncology | $2,460 |
| AstraZeneca UK Limited Dec 3, 2025 | Consulting Fee CALQUENCE · Oncology | $2,050 |
| Pfizer Inc. Nov 28, 2025 | Consulting Fee ADCETRIS · ONCOLOGY | $1,800 |
| Pfizer Inc. Nov 28, 2025 | Consulting Fee ADCETRIS · ONCOLOGY | $720 |
| Incyte Corporation Nov 24, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $2,055 |
| Incyte Corporation Nov 5, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $4,110 |
| Incyte Corporation Oct 27, 2025 | Travel and Lodging Monjuvi · Oncology · travel to Dothan, AL | $1,259 |
| Incyte Corporation Oct 21, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $4,110 |
| E.r. Squibb & Sons, L.l.c. Oct 21, 2025 | Compensation for services other than consulting (speaking, faculty) BREYANZI · Oncology | $3,623 |
| Incyte Corporation Oct 6, 2025 | Travel and Lodging Monjuvi · Oncology · travel to Andalusia, AL | $916 |
| E.r. Squibb & Sons, L.l.c. Oct 3, 2025 | Consulting Fee | $518 |
| Incyte Corporation Oct 1, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $2,740 |
| Adc Therapeutics America, Inc. Sep 30, 2025 | Honoraria ZYNLONTA · ONCOLOGY | $11,900 |
| Adc Therapeutics America, Inc. Sep 20, 2025 | Travel and Lodging ZYNLONTA · ONCOLOGY · travel to BOSTON, MA · in-kind | $159 |
| Adc Therapeutics America, Inc. Sep 19, 2025 | Travel and Lodging ZYNLONTA · ONCOLOGY · travel to BOSTON, MA · in-kind | $981 |
| Adc Therapeutics America, Inc. Sep 19, 2025 | Travel and Lodging ZYNLONTA · ONCOLOGY · travel to BOSTON, MA · in-kind | $371 |
| E.r. Squibb & Sons, L.l.c. Aug 28, 2025 | Consulting Fee | $716 |
| Incyte Corporation Aug 27, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $5,480 |
| Incyte Corporation Aug 18, 2025 | Travel and Lodging Monjuvi · Oncology · travel to Mobile, AL | $1,145 |
| E.r. Squibb & Sons, L.l.c. Aug 6, 2025 | Compensation for services other than consulting (speaking, faculty) BREYANZI · Oncology | $3,623 |
| Incyte Corporation Jul 31, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $1,028 |
| Genentech USA, Inc. Jul 28, 2025 | Consulting Fee Polivy; Columvi; Lunsumio · BioOncology | $2,460 |
| AbbVie Inc. Jul 14, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $363 |
| Incyte Corporation Jun 24, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $4,110 |
| Incyte Corporation Jun 23, 2025 | Travel and Lodging Monjuvi · Oncology · travel to Andalusia, AL | $973 |
| AstraZeneca Pharmaceuticals LP Jun 13, 2025 | Consulting Fee CALQUENCE · Oncology | $4,920 |
| AstraZeneca Pharmaceuticals LP Jun 13, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $3,280 |
| Genentech USA, Inc. Jun 12, 2025 | Consulting Fee | $760 |
| Novartis Pharmaceuticals Corporation Jun 10, 2025 | Consulting Fee | $2,100 |
| E.r. Squibb & Sons, L.l.c. May 30, 2025 | Compensation for services other than consulting (speaking, faculty) BREYANZI · Oncology | $4,140 |
| AstraZeneca Pharmaceuticals LP May 8, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $5,740 |
| AstraZeneca Pharmaceuticals LP May 5, 2025 | Travel and Lodging CALQUENCE · Oncology · travel to Decatur, AL · in-kind Company’s descriptionSpeaker Expenses | $723 |
| Kite Pharma, Inc. May 4, 2025 | Consulting Fee Yescarta · CELLT Company’s description;4099864;GTF;10411740 | $15,210 |
| Kite Pharma, Inc. May 2, 2025 | Travel and Lodging Yescarta · CELLT · travel to Tyson Corner, VA · in-kind Company’s description;4099608;GTF;10411740 | $493 |
| Kite Pharma, Inc. May 2, 2025 | Travel and Lodging Yescarta · CELLT · travel to Tyson Corner, VA · in-kind Company’s description;4099254;GTF;10411740 | $427 |
| Incyte Corporation Apr 23, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $5,480 |
| Incyte Corporation Apr 23, 2025 | Consulting Fee | $3,083 |
| Incyte Corporation Apr 23, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $2,740 |
| Incyte Corporation Apr 21, 2025 | Travel and Lodging Monjuvi · Oncology · travel to Pensacola, FL | $1,374 |
| Adc Therapeutics America, Inc. Apr 8, 2025 | Honoraria ZYNLONTA · ONCOLOGY | $5,475 |
| E.r. Squibb & Sons, L.l.c. Apr 7, 2025 | Compensation for services other than consulting (speaking, faculty) BREYANZI · Oncology | $3,623 |
| Incyte Corporation Apr 7, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $343 |
| Adc Therapeutics America, Inc. Apr 3, 2025 | Travel and Lodging ZYNLONTA · ONCOLOGY · travel to DECATUR, AL | $709 |
| E.r. Squibb & Sons, L.l.c. Mar 18, 2025 | Compensation for services other than consulting (speaking, faculty) BREYANZI · Oncology | $3,623 |
| Adc Therapeutics America, Inc. Mar 18, 2025 | Honoraria ZYNLONTA · ONCOLOGY | $1,825 |
| E.r. Squibb & Sons, L.l.c. Mar 14, 2025 | Compensation for services other than consulting (speaking, faculty) BREYANZI · Oncology | $8,280 |
| E.r. Squibb & Sons, L.l.c. Mar 14, 2025 | Compensation for services other than consulting (speaking, faculty) BREYANZI · Oncology | $3,623 |
| Incyte Corporation Feb 28, 2025 | Travel and Lodging travel to Austin, TX | $466 |
| AstraZeneca Pharmaceuticals LP Feb 27, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $250 |
| E.r. Squibb & Sons, L.l.c. Feb 26, 2025 | Travel and Lodging BREYANZI · Oncology · travel to Knoxville, TN | $2,618 |
| AstraZeneca Pharmaceuticals LP Feb 25, 2025 | Compensation for services other than consulting (speaking, faculty) CALQUENCE · Oncology Company’s descriptionSpeaker Fee | $300 |
| E.r. Squibb & Sons, L.l.c. Jan 30, 2025 | Compensation for services other than consulting (speaking, faculty) BREYANZI · Oncology | $3,623 |
| AbbVie Inc. Jan 3, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $363 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 21 industry-funded studies in 2025, from 11 companies. The companies reported $3,000,938 in research payments for these studies, mostly to the institutions running them.
- Phase i study of mogamulizumab in combination with brentuximab vedotin in cutaneous t-cell lymphoma and mycosis fungoides
Kyowa Kirin, Inc. - Phase i study of mogamulizumab m in combination with brentuximab vedotin bv in previously treated sezary syndrome ss and mycosis fungoides mf
Pfizer Inc. - A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Beone Medicines USA, Inc. · Recruiting · NCT05006716 - Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Taiho Oncology, Inc. - A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia
E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT02028455 - A Phase 1, Open-Label, Dose Finding Study of CC-95251, A Monoclonal Antibody Directed Against SIRPa, Alone and in Combination with Cetuximab or Rituximab in Subjects with Advanced Solid and Hematologic Cancers
Celgene Corporation - Relapsed or refractory (r/r) b-cell non-hodgkin lymphoma (nhl)
Takeda Pharmaceuticals U.S.A., Inc. - INCB50465-801, Ph2, Roll-Over Study
Incyte Corporation - Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL)
Celgene Corporation - A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Beone Medicines Ltd. · Recruiting · NCT06742996
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.